Short Interest in Oragenics, Inc. (NYSEAMERICAN:OGEN) Increases By 303.6%

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 139,273 shares, a growth of 303.6% from the November 30th total of 34,508 shares. Based on an average trading volume of 114,186 shares, the days-to-cover ratio is presently 1.2 days. Approximately 3.7% of the company’s shares are sold short. Approximately 3.7% of the company’s shares are sold short. Based on an average trading volume of 114,186 shares, the days-to-cover ratio is presently 1.2 days.

Oragenics Stock Performance

Oragenics stock opened at $0.86 on Friday. Oragenics has a 52 week low of $0.82 and a 52 week high of $18.90. The firm has a market capitalization of $3.58 million, a price-to-earnings ratio of -0.07 and a beta of 0.92. The company has a 50 day moving average price of $1.03 and a 200 day moving average price of $1.48.

Oragenics (NYSEAMERICAN:OGEN) last released its earnings results on Friday, November 7th. The company reported ($1.96) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Oragenics

Several institutional investors and hedge funds have recently bought and sold shares of OGEN. Bank of America Corp DE boosted its holdings in shares of Oragenics by 7,374.0% during the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after purchasing an additional 15,338 shares during the period. Sabby Management LLC purchased a new stake in Oragenics in the 3rd quarter worth approximately $77,000. Finally, Clear Street LLC acquired a new stake in shares of Oragenics during the 2nd quarter valued at $270,000. Hedge funds and other institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.